- Trials with a EudraCT protocol (39)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
39 result(s) found for: Tissue Plasminogen Activator.
Displaying page 2 of 2.
«
Previous
1
2
EudraCT Number: 2007-001996-13 | Sponsor Protocol Number: Tirofiban-Urokinasi 2007 | Start Date*: 2007-06-06 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA SENESE | |||||||||||||
Full Title: Intravenous glycoprotein IIbIIIa inhibitor (Tirofiban) combined with low dose of intra-arterial Urokinase for the endovascolar treatment of patients with acute major ischemic stroke | |||||||||||||
Medical condition: patients with major ischemic stroke not suitable for other authorized treatment for riperfusion of the ischemic area | |||||||||||||
|
|||||||||||||
Population Age: In utero, Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002304-16 | Sponsor Protocol Number: 130873-2004 | Start Date*: 2005-06-14 |
Sponsor Name:South Tees Hospitals NHS Foundation Trust | ||
Full Title: The STARS (STeroids Against Re-Stenosis) Trial [THE USE OF Peri-PROCEDURAL ORAL CORTICOSTERIODS TO PREVENT IN-SEGMENT RESTENOSIS AFTER PERCUTANEOUS CORONARY INTERVENTION.] | ||
Medical condition: coronary artery disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004917-10 | Sponsor Protocol Number: TIGER | Start Date*: 2023-06-29 | |||||||||||
Sponsor Name:King's College London [...] | |||||||||||||
Full Title: Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative age-Related macular degeneration (TIGER): a phase 3, pan-European, two-gro... | |||||||||||||
Medical condition: Submacular haemorrhage secondary to exudative age-related macular degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004078-24 | Sponsor Protocol Number: TAPAS | Start Date*: 2013-01-24 | ||||||||||||||||
Sponsor Name:King's College London [...] | ||||||||||||||||||
Full Title: Intravitreal Tissue Plasminogen Activator (tPA), Perfluoropropane (C3F8), and Ranibizumab for Neovascular Age-Related Macular Degeneration and Submacular Haemorrhage (TAPAS): A Randomized, Double-M... | ||||||||||||||||||
Medical condition: Sub-macular haemorrhage secondary to wet macular degeneration | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002657-36 | Sponsor Protocol Number: HMRI2012101/1 | Start Date*: 2015-11-13 | |||||||||||
Sponsor Name:University of Newcastle | |||||||||||||
Full Title: Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) Trial | |||||||||||||
Medical condition: Acute Ischaemic Stroke | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) SE (Prematurely Ended) FI (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001989-42 | Sponsor Protocol Number: TEA-Stroke | Start Date*: 2013-08-02 | |||||||||||
Sponsor Name:Boris Modrau | |||||||||||||
Full Title: Theophylline Effect in Acute Ischemic Stroke Trial | |||||||||||||
Medical condition: Acute ischemic stroke patients eligible for standard intravenous recombinant tissue plasminogen activator (rtPA) thrombolytic therapy with magnet resonance imaging (MRI)-proved infarction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005682-12 | Sponsor Protocol Number: H-2-2012_089 | Start Date*: 2013-07-03 | ||||||||||||||||||||||||||
Sponsor Name:Dept. of Clinical Immunology | ||||||||||||||||||||||||||||
Full Title: THE EFFECT OF PLASMA ON THE ENDOTHELIUM IN CRITICAL ILLNESS | ||||||||||||||||||||||||||||
Medical condition: Pilot study in healthy subjects with a perspective for treating of serious conditions such as sepsis, septic shock, trauma and severe haemorrhage | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male | |||||||||||||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001514-15 | Sponsor Protocol Number: 101SK201 | Start Date*: 2013-11-26 | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) on Reducing Infarct Volume in Acute Ischem... | |||||||||||||
Medical condition: Acute Ischemic Stroke | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002061-22 | Sponsor Protocol Number: RC17_0061 | Start Date*: 2017-09-12 | |||||||||||
Sponsor Name:CHU de Nantes | |||||||||||||
Full Title: A phase III randomized, blind, double dummy, multicenter study assessing the efficacy and safety of IV thrombolysis (alteplase) in patients with acute central retinal artery occlusion | |||||||||||||
Medical condition: acute central retinal artery occlusion | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000816-96 | Sponsor Protocol Number: P160924 | Start Date*: 2020-04-27 |
Sponsor Name:AP-HP/ DRCI | ||
Full Title: A reduced dose of thrombolytic treatment for patients with intermediate high-risk acute pulmonary embolism | ||
Medical condition: Intermediate high-risk acute pulmonary embolism | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) AT (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) SI (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2007-006731-31 | Sponsor Protocol Number: tandem-1 | Start Date*: 2008-05-19 | |||||||||||
Sponsor Name:Fundació Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol | |||||||||||||
Full Title: Estudio doble ciego, aleatorizado, controlado con placebo de dosis escaladas de deferoxamina intravenosa en pacientes con ictus isquémico agudo tratado con activador tisular del plasminógeno. Doubl... | |||||||||||||
Medical condition: La deferoxamina es un neuroprotector en modelos animales de isquemia/reperfusión cerebral. Si la deferoxamina es segura y bien tolerada en pacientes con ictus agudo puede significar una nueva estra... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001547-12 | Sponsor Protocol Number: DC2017RACELINES01 | Start Date*: 2017-12-21 |
Sponsor Name:VU University Medical Center | ||
Full Title: A phase 4, monocenter, randomized, double-blind, comparator-controlled, 3-armed parallel mechanistic intervention trial to assess the effect of 8-week empagliflozin (SGLT-2 inhibitor) monotherapy, ... | ||
Medical condition: Type 2 Diabetes Mellitus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-020763-20 | Sponsor Protocol Number: 10072DMcA-CS | Start Date*: 2010-10-04 |
Sponsor Name:National University of Ireland, Galway | ||
Full Title: Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP 2) | ||
Medical condition: Acute lung injury | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-002994-39 | Sponsor Protocol Number: Cx611-0204 | Start Date*: 2016-04-06 |
Sponsor Name:TIGENIX, S.A.U. | ||
Full Title: A phase Ib/IIa, randomised, double blind, parallel group, placebo controlled, multicentre study to assess the safety and efficacy of expanded Cx611 allogeneic adipose-derived stem cells (eASCs) for... | ||
Medical condition: Severe community-acquired bacterial pneumonia requiring mechanical ventilation and/or vasopressors. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) BE (Completed) LT (Completed) GB (Completed) FR (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-017454-12 | Sponsor Protocol Number: U01–NS052220 | Start Date*: 2011-02-04 | ||||||||||||||||
Sponsor Name:University of Cincinnati - Academic Medical Center -Department of Neurology | ||||||||||||||||||
Full Title: INTERVENTIONAL MANAGEMENT OF STROKE TRIAL CLINICAL PROTOCOL A phase III, randomized, multi-center, open label, 900 subject clinical trial that will examine whether a combined intravenous (IV) and i... | ||||||||||||||||||
Medical condition: Ischemic Stroke | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended) ES (Temporarily Halted) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005036-26 | Sponsor Protocol Number: FXT-05 | Start Date*: 2011-11-29 | ||||||||||||||||||||||||||
Sponsor Name:Funxional Therapeutics Ltd | ||||||||||||||||||||||||||||
Full Title: An Exploratory Phase IIa Study to Investigate the Biological Activity of Oral FX125L in Adult Patients with Chronic Inflammatory Disease | ||||||||||||||||||||||||||||
Medical condition: Asthma Chronic obstructive pulmonary disease Rheumatoid arthritis Psoriasis | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002148-56 | Sponsor Protocol Number: ACT-CS-005 | Start Date*: 2021-07-22 | |||||||||||
Sponsor Name:ACTICOR BIOTECH | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE BLIND, MULTICENTER, MULTINATIONAL, PLACEBO CONTROLLED, PARALLEL GROUP, SINGLE DOSE, ADAPTIVE EFFICACY AND SAFETY STUDY OF GLENZOCIMAB USED AS AN ADD-ON THERAPY ON TOP OF STANDA... | |||||||||||||
Medical condition: Acute ischemic stroke | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) SK (Completed) ES (Ongoing) CZ (Completed) DK (Completed) BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003930-26 | Sponsor Protocol Number: DU-176B-C-U4001 | Start Date*: 2017-05-15 | |||||||||||
Sponsor Name:Daiichi Sankyo Inc. | |||||||||||||
Full Title: Edoxaban Versus Standard of Care and Their Effects on Clinical Outcomes in Patients Having Undergone Transcatheter Aortic Valve Implantation – In Atrial Fibrillation. ENVISAGE-TAVI AF | |||||||||||||
Medical condition: Patients with atrial fibrillation (AF) and indication to chronic oral anticoagulant after transcatheter aortic valve implantation (TAVI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) AT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012086-66 | Sponsor Protocol Number: T05018-1001 | Start Date*: 2009-12-01 | |||||||||||
Sponsor Name:Grifols Inc | |||||||||||||
Full Title: A Phase 1/2a, Open Label, Dose Escalation, Safety Study of Intra-thrombus Plasmin (Human) Administration in Acute, Middle Cerebral Artery, Ischemic Stroke | |||||||||||||
Medical condition: Thrombus in acute ischemic stroke of the middle cerebral artery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) FR (Completed) SK (Completed) AT (Completed) | |||||||||||||
Trial results: Removed from public view |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
«
Previous
1
2
